Dale Erickson, MD
Nephrology · Albuquerque, NMNPI 1659393197
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,478 and has fallen 80.1% since, to $295 in 2025.
Across 261 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$812
- Daiichi Sankyo Inc.$605
- Vifor Pharma, Inc.$552
- Bayer$446
- Nxstage Medical, Inc.$399
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,796100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 52 | $1,143 |
| Amgen(2 entities) | 28 | $812 |
| Daiichi Sankyo Inc. | 54 | $605 |
| Vifor Pharma, Inc. | 30 | $552 |
| Bayer | 15 | $446 |
| Nxstage Medical, Inc. | 5 | $399 |
| Aurinia Pharma U.S., Inc. | 12 | $327 |
| Novartis | 8 | $217 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Boehringer Ingelheim | 1 | $121 |
| Calliditas Therapeutics US Inc. | 3 | $94 |
| Sanofi | 4 | $93 |
| Travere Therapeutics, Inc. | 6 | $92 |
| Fresenius USA Marketing, Inc. | 5 | $91 |
| GSK | 6 | $84 |
| Baxter Healthcare | 1 | $78 |
| Ardelyx, Inc. | 1 | $67 |
| Veloxis Pharmaceuticals, Inc. | 2 | $63 |
| Novo Nordisk | 2 | $51 |
| Kyowa Kirin, Inc. | 1 | $50 |
| Johnson & Johnson | 3 | $45 |
| Akebia Therapeutics Inc | 3 | $44 |
| Mallinckrodt Enterprises LLC | 3 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Cormedix Inc. | 1 | $20 |
| Amicus Therapeutics, Inc. | 1 | $17 |
| Renalytix AI, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Chiesi USA, Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$242
- Tavneos$231
- LOKELMA$123
- LUPKYNIS$122
- JARDIANCE$121
- PUREFLOW SL$109
- NXSTAGE SYSTEM ONE$109
How this compares
$5,802 in reported general payments places this provider in the 80th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UloricFebuxostat | 12 | $7,142 |
| Calcitriol | 192 | $3,626 |
| Losartan Potassium | 147 | $2,609 |
| Cinacalcet Hcl | 30 | $2,579 |
| Febuxostat | 15 | $2,314 |
| Sevelamer Carbonate | 13 | $2,220 |
| Potassium Citrate ErPotassium Citrate | 18 | $2,023 |
| Allopurinol | 144 | $1,546 |
| Furosemide | 134 | $1,397 |
| Carvedilol | 91 | $1,267 |
| Hydralazine Hcl | 44 | $950 |
| Bumetanide | 20 | $940 |
| Lisinopril | 58 | $894 |
| Metoprolol Succinate | 28 | $823 |
| Atorvastatin Calcium | 27 | $685 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Lei ChenAlbuquerque$5K
- Sonam KundelingAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.